Evidence map›Paper›PMID 27543619›Full record

ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2016

Presurgical Biomarker Performance in the Detection of Gleason Upgrading in Prostate Cancer.

Kristina Wittig, Johnathan L Yamzon, David D Smith, Daniel R Jeske, Steven S Smith

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Prevalence and clinical application ofAsian journal of andrology
    Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Kristina WittigDivision of Urology, Department of Surgery, City of Hope, Duarte, California.
Johnathan L YamzonDivision of Urology, Department of Surgery, City of Hope, Duarte, California.
David D SmithDivision of Biostatistics, Department of Information Sciences, City of Hope, Duarte, California.
Daniel R JeskeDivision of Biostatistics, Department of Information Sciences, City of Hope, Duarte, California.
Steven S SmithDivision of Urology, Department of Surgery, City of Hope, Duarte, California. ssmith@coh.org.
City Of Hope National Medical Center · USCity of Hope · USUniversity of California, Riverside · US

Funding

EPS Markers in the Early Detection of Prostate CancerR01CA102521 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI SMITH, STEVEN SIDNEY · 2004 to 2006
$803k
Thiroredoxin Targeted Nanoparticles for Cancer ResearchR03CA136055 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI SMITH, STEVEN SIDNEY · 2008 to 2009
$187k
NCI NIH HHS R01 CA102521NCI NIH HHS R03 CA136055
6 · The paper itself

Abstract

backgroundGleason Score (GS) upgrading is generally considered a trigger for exit to definitive treatment during active surveillance (AS). Predicting the potential for GS upgrading would be of value in assessing AS eligibility.

methodsWe assessed the performance of biomarkers in presurgical specimens of expressed prostatic secretion (EPS) in this setting.

resultsAlthough EPS volume, total recovered RNA, and RNA expression biomarkers (TMPRSS2: ERG, PCA3, PSA) have been successful in both biopsy outcome prediction, and in the prediction of upstaging in active surveillance eligible patients, they were unable to predict upgrading in patients eligible for active surveillance under National Comprehensive Cancer Network guidelines.

conclusionsThese biomarkers do not improve the prediction of upgrading over indications from standard clinical parameters. IMPACT: Additional biomarkers will be needed in this area. Cancer Epidemiol Biomarkers Prev; 25(12); 1643-5. ©2016 AACR.

Indexed as

Antigens, NeoplasmBiomarkers, TumorGene ExpressionHumansMaleNeoplasm GradingPrognosisProstate-Specific AntigenProstatic NeoplasmsSensitivity and SpecificitySerine EndopeptidasesTranscriptional Regulator ERGAntigens, NeoplasmBiomarkers, TumorERG protein, humanprostate cancer antigen 3, humanProstate-Specific AntigenSerine EndopeptidasesTMPRSS2 protein, humanTranscriptional Regulator ERG

Identifiers

PMID27543619
PMCPMC5704940
OpenAlexW2508443973

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.